MX2020013896A - Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. - Google Patents

Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.

Info

Publication number
MX2020013896A
MX2020013896A MX2020013896A MX2020013896A MX2020013896A MX 2020013896 A MX2020013896 A MX 2020013896A MX 2020013896 A MX2020013896 A MX 2020013896A MX 2020013896 A MX2020013896 A MX 2020013896A MX 2020013896 A MX2020013896 A MX 2020013896A
Authority
MX
Mexico
Prior art keywords
pyrrolo
intermediates
manufacturing process
pyrimidine compound
crystalline form
Prior art date
Application number
MX2020013896A
Other languages
English (en)
Inventor
Kris Nicole Jones
Kapildev Kashmirilal Arora
Jacob Cole Deforest
Andrew Kevern Hills
Brian Patrick Jones
Chad Arthur Lewis
Anil Mahadeo Rane
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2020013896A publication Critical patent/MX2020013896A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un proceso de fabricación de intermediarios para preparar una forma cristalina o no cristalina de N-((1S,3S)-3-(metil(7H-pirrolo [2,3-d]pirimidin-4-il)amino)ciclobutil)propan-1-sulfonamida; formas de sal y composiciones farmacéuticas que comprenden la forma cristalina, y métodos para el uso del compuesto preparado de una forma cristalina en el tratamiento de diversas enfermedades.
MX2020013896A 2018-07-06 2019-07-03 Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. MX2020013896A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862694698P 2018-07-06 2018-07-06
US201862776642P 2018-12-07 2018-12-07
US201962855071P 2019-05-31 2019-05-31
PCT/IB2019/055683 WO2020008391A1 (en) 2018-07-06 2019-07-03 Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof

Publications (1)

Publication Number Publication Date
MX2020013896A true MX2020013896A (es) 2021-03-09

Family

ID=67928862

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020013896A MX2020013896A (es) 2018-07-06 2019-07-03 Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
MX2023006842A MX2023006842A (es) 2018-07-06 2020-12-16 Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023006842A MX2023006842A (es) 2018-07-06 2020-12-16 Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.

Country Status (13)

Country Link
US (2) US10815240B2 (es)
EP (1) EP3817810A1 (es)
JP (1) JP7437646B2 (es)
KR (1) KR102568464B1 (es)
CN (1) CN112384282A (es)
AU (1) AU2019299666A1 (es)
BR (1) BR112020025701A2 (es)
CA (1) CA3105161C (es)
IL (1) IL279926B2 (es)
MX (2) MX2020013896A (es)
TW (1) TWI709562B (es)
WO (1) WO2020008391A1 (es)
ZA (1) ZA202100196B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3969458A4 (en) 2019-05-13 2023-05-17 Borah, Inc. CHEMICAL COMPOUNDS
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
CN112279785B (zh) * 2020-10-29 2022-08-16 苏利制药科技江阴有限公司 3,3-二氟环丁胺盐酸盐中间体及其合成方法和3,3-二氟环丁胺盐酸盐合成方法
CN113583992B (zh) * 2021-07-15 2023-06-27 华东理工大学 一种还原胺化酶及其在仲胺合成中的应用
CN117980293A (zh) * 2021-09-10 2024-05-03 上海海和药物研究开发股份有限公司 具有enpp1抑制活性的异羟基肟酸类化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP4126781B2 (ja) 1998-10-26 2008-07-30 宇部興産株式会社 １−スルホニルピラゾール誘導体及びその製造方法
JP2003005323A (ja) 2001-06-20 2003-01-08 Konica Corp 熱現像写真感光材料及び画像形成方法
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
CA2768877A1 (en) 2009-08-10 2011-02-17 Bellus Health Inc. Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
US9006456B2 (en) 2011-07-08 2015-04-14 Syngenta Participations Ag Processes for the preparation of thietanamine
SI3290421T1 (sl) * 2013-02-22 2019-03-29 Pfizer Inc. Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK)
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa

Also Published As

Publication number Publication date
ZA202100196B (en) 2022-09-28
CA3105161A1 (en) 2020-01-09
EP3817810A1 (en) 2021-05-12
IL279926B1 (en) 2023-08-01
US11254684B2 (en) 2022-02-22
US20210009601A1 (en) 2021-01-14
MX2023006842A (es) 2023-06-22
JP7437646B2 (ja) 2024-02-26
KR20210029234A (ko) 2021-03-15
IL279926B2 (en) 2023-12-01
KR102568464B1 (ko) 2023-08-21
CN112384282A (zh) 2021-02-19
AU2019299666A1 (en) 2021-01-07
IL279926A (en) 2021-03-01
CA3105161C (en) 2022-11-15
JP2020007308A (ja) 2020-01-16
WO2020008391A1 (en) 2020-01-09
BR112020025701A2 (pt) 2021-03-16
US20220127274A1 (en) 2022-04-28
TWI709562B (zh) 2020-11-11
US10815240B2 (en) 2020-10-27
TW202017929A (zh) 2020-05-16
US20200123159A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
MX2023006842A (es) Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
PH12019500930A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
NZ766835A (en) Pharmaceutical compounds
MX2021003241A (es) Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo.
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
TNSN06226A1 (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
MX370390B (es) Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados.
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
MY150059A (en) Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
EP4302761A3 (en) Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
GEP20217327B (en) Spirocycle compounds and methods of making and using same
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
MX2021002042A (es) Inhibidores de arginasa y sus metodos de uso.
EA202190323A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
PH12020552236A1 (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
MX2018009912A (es) Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina.
EA201990364A1 (ru) КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
EA202190322A1 (ru) ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ TRK
PH12020551736A1 (en) The crystalline forms of a compound